# US 2022/0064325 A1 · Novel polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064325 A1
- Document ID: US20220064325A1
- Status: Published application
- Kind: A1
- Application number: 17/312,184
- Filed: 2019-12-17
- Published: 2022-03-03
- Earliest claimed: 2018-12-17
- Assignees: Alligator Bioscience AB
- Applicants: Alligator Bioscience AB
- Inventors: Anna Sall; Peter Ellmark; Adnan Deronic; Fredrika Carlsson; Karin Hagerbrand; Laura Von Schantz
- Web page: https://patentgrep.com/patent/US20220064325A1

## CPC

- C07K 16/3092: {against tumour-associated mucins}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/2887: {against CD20}
- C07K 16/30: from tumour cells
- C07K 16/3007: {Carcino-embryonic Antigens}
- C07K 16/3015: {Breast}
- C07K 16/32: against translation products of oncogenes
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/31: multispecific
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of targeting a dendritic cell, and a second binding domain, designated B2, which is capable of targeting a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.

## Claims

### Claim 1

A bispecific polypeptide comprising:
(i) a first binding domain, designated B1, capable of targeting a dendritic cell (DC); and
(ii) a second binding domain, designated B2, capable of targeting a tumour-cell associated antigen (TAA);
wherein the bispecific polypeptide is capable of inducing
(a) tumour-localised activation of dendritic cells, and/or
(b) internalisation of tumour debris and/or internalisation of extracellular vesicles comprising tumour-cell associated antigens;
for use in treating a patient with a neoplastic disorder comprising tumour cells and/or preventing a neoplastic disorder comprising tumour cells in a patient;
wherein the neoplastic disorder is characterised in that one or more tumour cell from the patient comprises a TAA which is expressed at an average density above 30,000 per tumour cell.

### Claim 2

A method of treating a neoplastic disorder in a patient and/or preventing a neoplastic disorder comprising tumour cells in a patient and/or diagnosing a neoplastic disorder comprising tumour cells in a patient, comprising the step of administering to the subject an effective amount of a bispecific polypeptide comprising:
(i) a first binding domain, designated B1, capable of targeting a dendritic cell (DC); and
(ii) a second binding domain, designated B2, capable of targeting a tumour-cell associated antigen (TAA);
wherein the bispecific polypeptide is capable of inducing
(a) tumour-localised activation of dendritic cells, and/or
(b) internalisation of tumour debris and/or internalisation of extracellular vesicles comprising tumour-cell associated antigens;
wherein the neoplastic disorder is characterised in that one or more tumour cell from the patient comprises a TAA which is expressed at an average density above 30,000 per tumour cell.

### Claim 3

A use of a bispecific polypeptide comprising:
(iv) a first binding domain, designated B1, capable of targeting a dendritic cell (DC); and
(v) a second binding domain, designated B2, capable of targeting a tumour-cell associated antigen (TAA);
wherein the bispecific polypeptide is capable of inducing
(a) tumour-localised activation of dendritic cells, and/or
(b) internalisation of tumour debris and/or internalisation of extracellular vesicles comprising tumour-cell associated antigens;
in the preparation of a medicament treating a neoplastic disorder in a patient and/or preventing a neoplastic disorder comprising tumour cells in a patient;
wherein the neoplastic disorder is characterised in that one or more tumour cell from the patient comprises a TAA which is expressed at an average density above 30,000 per tumour cell.

### Claim 4 (depends on 1, 2, 3)

The bispecific polypeptide according to claim 1 or the method according to claim 2 or the use according to claim 3, wherein the average density is above 50,000 per tumour cell, optionally wherein the average density is above 150,000, 200,000, 250,000, 300,000, 350,000, 400,000, 450,000, 500,000, 550,000, 600,000, 650,000, 700,000, 750,000, 800,000, 850,000, 900,000, 950,000, 1,000,000, 1,050,000, 1,100,000, 1,150,000, 1,200,000, 1,250,000, 1,300,000, 1,350,000, 1,400,000, 1,450,000, 1,500,000, 1,550,000, 1,600,000, 1,650,000, 1,700,000, 1,750,000, 1,800,000, 1,850,000, 1,900,000, 1,950,000, 2,000,000, 2,050,000, 2,100,000, 2,150,000, 2,200,000, 2,250,000, 2,300,000, 2,350,000, 2,400,000, 2,450,000, 2,500,000, 2,550,000, 2,600,000, 2,650,000, 2,700,000, 2,750,000, 2,800,000, 2,850,000, 2,900,000, 2,950,000, or 3,000,000 per tumour cell.

### Claim 5 (depends on 4)

The bispecific polypeptide or method or use according to claim 4, wherein the average density is above 1,500,000 per tumour cell.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The bispecific polypeptide according to any one of claim 1, 4 or 5 or the method according to any one of claim 2, 4 or 5 or the use according to any one of claim 3-5, wherein binding domain B1 is capable of inducing internalisation of extracellular vesicles comprising tumour-cell associated antigens.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The bispecific polypeptide according to any one of claim 1 or 4-6 or the method according to any one of claim 2 or 4-6 or the use according to any one of claim 3-6, wherein the bispecific polypeptide is capable of inducing internalisation and cross-presentation of tumour antigens.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The bispecific polypeptide according to any one of claim 1 or 4-7 or the method according to any one of claim 2 or 4-7 or the use according to any one of claim 3-7, wherein the bispecific polypeptide is capable of inducing activation of effector T cells.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The bispecific polypeptide according to any one of claim 1 or 4-8 or the method according to any one of claim 2 or 4-8 or the use according to any one of claim 3-8, wherein the bispecific polypeptide is capable of inducing expansion of tumour antigen-specific T cells.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The bispecific polypeptide according to any one of claim 1 or 4-9 or the method according to any one of claim 2 or 4-9 or the use according to any one of claim 3-9, wherein the TAA to be targeted exhibits a sufficiently high density on tumour cells to enable:
(a) tumour-localised activation of dendritic cells, and/or
(b) internalisation of tumour debris and/or internalisation of extracellular vesicles comprising tumour-cell associated antigens.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The bispecific polypeptide according to any one of claim 1 or 4-10 or the method according to any one of claim 2 or 4-10 or the use according to any one of claim 3-10, wherein the extracellular vesicles are selected from: apoptotic bodies, microvesicles and exosomes.

### Claim 12 (depends on 12)

The bispecific polypeptide or method or use according to claim 12, wherein the extracellular vesicles are exosomes.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The bispecific polypeptide according to any one of claim 1 or 4-12 or the method according to any one of claim 2 or 4-12 or the use according to any one of claim 3-12, wherein the TAA to be targeted exhibits a high density on tumour cells and can be detected on extracellular vesicles in a sample collected from a patient, optionally wherein said extracellular vesicles are exosomes in a sample collected from a patient.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The bispecific polypeptide according to any one of claim 1 or 4-13 or the method according to any one of claim 2 or 4-13 or the use according to any one of claim 3-13, wherein the TAA to be targeted has an average density of above 30,000 per tumour cell (for example, 100,000 per tumour cell) and can be detected on extracellular vesicles in a sample collected from a patient, optionally wherein said extracellular vesicles are exosomes in a sample collected from a patient.

### Claim 15 (depends on 13, 14)

The bispecific polypeptide or method or use according to claim 13 or 14, wherein the concentration of TAA-positive extracellular vesicles is at least 1×106 EVs/ml or 1×107 EVs/ml or 1×108 EVs/ml or 1×109 EVs/ml or 1×1010 EVs/ml in a sample collected from a patient.

### Claim 16 (depends on 13, 14, 15)

The bispecific polypeptide or method or use according to any one of claims 13-15, wherein the TAA is detected on at least 0.25% or 0.5% or 1% or 2% or 3% or 4% or 5% or 6% or 7% or 8% or 9% or 10% of the extracellular vesicles in a sample collected from a patient.

### Claim 17 (depends on 13, 14, 15, 16)

The bispecific polypeptide or method or use according to any one of claims 13-16, wherein the total protein concentration of TAA-positive EV is at least 0.075 mg/ml, 0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.6 mg/ml, 0.7 mg/ml, 0.8 mg/ml, 0.9 mg/ml, 1 mg/ml or 1.5 mg/rd.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The bispecific polypeptide according to any one of claim 1 or 4-17 or the method according to any one of claim 2 or 4-17 or the use according to any one of claim 3-17, wherein the first and/or second binding domains are/is selected from the group consisting of antibodies and antigen-binding fragments thereof.

### Claim 19 (depends on 18)

The bispecific polypeptide or method or use according to claim 18, wherein the antigen-binding fragment is selected from the group consisting of: Fv fragments (such as a single chain Fv fragment, or a disulphide-bonded Fv fragment), Fab-like fragments (such as a Fab fragment; a Fab′ fragment or a F(ab)2 fragment) and domain antibodies.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The bispecific polypeptide according to any one of claim 1 or 4-19 or the method according to any one of claim 2 or 4-19 or the use according to any one of claim 3-19, wherein the polypeptide is a bispecific antibody.

### Claim 21 (depends on 20)

The bispecific polypeptide or method or use according to claim 20, wherein:
(a) binding domain B1 and/or binding domain B2 is an intact IgG antibody;
(b) binding domain B1 and/or binding domain B2 is an Fv fragment;
(c) binding domain B1 and/or binding domain B2 is a Fab fragment; and/or
(d) binding domain B1 and/or binding domain B2 is a single domain antibody.

### Claim 22 (depends on 20, 21)

The bispecific polypeptide or method or use according to claim 20 or 21, wherein the bispecific antibody comprises a human Fc region or a variant of a said region, where the region is an IgG1, IgG2, IgG3 or IgG4 region, preferably an IgG1 or IgG4 region.

### Claim 23 (depends on 22)

The bispecific polypeptide or method or use according to claim 22, wherein the Fc exhibits no or very low affinity for FcγR.

### Claim 24 (depends on 22, 23)

The bispecific polypeptide or method or use according to claim 22 or 23, wherein the Fc region is a variant of a human IgG1 Fc region comprising a mutation at one or more of the following positions:
L234, L235, P239, D265, N297 and/or P329.

### Claim 25 (depends on 24)

The bispecific polypeptide or method or use according to claim 24, wherein alanine is present at the mutated position(s).

### Claim 26 (depends on 25)

The bispecific polypeptide or method or use according to claim 25, wherein the Fc region is a variant of a human IgG1 Fc region comprising the double mutations L234A and L235A.

### Claim 27 (depends on 20, 21, 22, 23, 24, 25, 26)

The bispecific polypeptide or method or use according to any one of claims 20-26, wherein the bispecific antibody is selected from the groups consisting of:
(a) bivalent bispecific antibodies, such as IgG-scFv bispecific antibodies (for example, wherein B1 is an intact IgG and B2 is an scFv attached to B1 at the N-terminus of a light chain and/or at the C-terminus of a light chain and/or at the N-terminus of a heavy chain and/or at the C-terminus of a heavy chain of the IgG, or vice versa);
(b) monovalent bispecific antibodies, such as a DuoBody® or a ‘knob-in-hole’ bispecific antibody (for example, an scFv-KIH, scFv-KIHr, a BiTE-KIH or a BiTE-KIM;
(c) scFv2-Fc bispecific antibodies (for example, ADAPTIR™ bispecific antibodies);
(d) BiTE/scFv2 bispecific antibodies;
(e) DVD-Ig bispecific antibodies;
(f) DART-based bispecific antibodies (for example, DART2-Fc or DART);
(g) FcAb2 bispecific antibodies;
(h) DNL-Fab3 bispecific antibodies; and
(i) scFv-HSA-scFv bispecific antibodies.

### Claim 28 (depends on 27)

The bispecific polypeptide or method or use according to claim 27, wherein the bispecific antibody is an IgG-scFv bispecific antibody.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The bispecific polypeptide according to any one of claim 1 or 4-28 or the method according to any one of claim 2 or 4-28 or the use according to any one of claim 3-28, wherein binding domain B1 and binding domain B2 are fused directly to each other.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The bispecific polypeptide according to any one of claim 1 or 4-28 or the method according to any one of claim 2 or 4-28 or the use according to any one of claim 3-28, wherein binding domain B1 and binding domain B2 are joined via a polypeptide linker.

### Claim 31 (depends on 30)

The bispecific polypeptide or method or use according to claim 30, wherein the linker is selected from the group consisting of the amino acid sequence SGGGGSGGGGS (SEQ ID NO: 172), SGGGGSGGGGSAP (SEQ ID NO: 173), NFSQP (SEQ ID NO: 174), KRTVA (SEQ ID NO: 175), GGGSGGGG (SEQ ID NO: 176), GGGGSGGGGS (SEQ ID NO: 177), GGGGSGGGGSGGGGS (SEQ ID NO: 178), GSTSGSGKPGSGEGSTKG (SEQ ID NO: 179), THTCPPCPEPKSSDK (SEQ ID NO: 180), GGGS (SEQ ID NO: 181), EAAKEAAKGGGGS (SEQ ID NO: 182), EAAKEAAK (SEQ ID NO: 183), or (SG)m, where m=1 to 7.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The bispecific polypeptide according to any one of claim 1 or 4-30 or the method according to any one of claim 2 or 4-30 or the use according to any one of claim 3-30, wherein one of B1 or B2 is an immunoglobulin molecule, and one of B1 or B2 is a Fab fragment, wherein the Fab fragment is fused to the C-terminus of the heavy chain of the immunoglobulin via the light chain of the Fab fragment.

### Claim 33 (depends on 32)

The bispecific polypeptide or method or use according to claim 32, wherein the bispecific polypeptide comprises one or more mutations to promote association of the heavy chain polypeptide of the immunoglobulin with the light chain polypeptide of the immunoglobulin and/or to promote association of the heavy chain polypeptide of the Fab with the light chain polypeptide of the Fab.

### Claim 34 (depends on 33)

The bispecific polypeptide or method or use according to claim 33, wherein the one or more mutations prevent the formation of aggregates and a Fab by-product.

### Claim 35 (depends on 34)

The bispecific polypeptide or method or use according to claim 34, wherein the mutations prevent formation of aggregates and Fab by-products by generating steric hindrance and/or incompatibility between charges.

### Claim 36 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The bispecific polypeptide or method or use according to any one of claims 33-56, wherein the antibody comprises one or more mutation pairs each comprising two functionally compatible mutations.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The bispecific polypeptide according to any one of claim 1 or 4-36 or the method according to any one of claim 2 or 4-36 or the use according to any one of claim 3-36, wherein the binding of the polypeptide by binding domain B1 is capable of inducing
(a) tumour-specific immune activation; and/or
(b) activation of dendritic cells; and/or
(c) internalisation of associated tumour debris and/or extracellular vesicles containing tumour cell-associated antigens as well as tumour neoantigens; and/or
(d) cross-presentation of peptides derived from internalised tumour antigens on MHC; and/or
(e) priming and activation of effector T cells; and/or
(f) direct tumoricidal effects, selected from the list consisting of: apoptosis, antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The bispecific polypeptide according to any one of claim 1 or 4-37 or the method according to any one of claim 2 or 4-37 or the use according to any one of claim 3-37, wherein binding domain B1 binds to the DC target with a KD of less than 100×10−9M or less than 50×10−9M or less than 25×10−9M, preferably less than 10, 9, 8, 7, or 6×10−9M, more preferably less than 5, 4, 3, 2, or 1×10−9M, most preferably less than 9×10−10M.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The bispecific polypeptide according to any one of claim 1 or 4-38 or the method according to any one of claim 2 or 4-38 or the use according to any one of claim 3-38, wherein binding domain B1 binds a DC target which is capable of mediating internalisation.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The bispecific polypeptide according to any one of claim 1 or 4-39 or the method according to any one of claim 2 or 4-39 or the use according to any one of claim 3-39, wherein binding domain B1 binds a DC target which is capable of mediating cross-presentation.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The bispecific polypeptide according to any one of claim 1 or 4-40 or the method according to any one of claim 2 or 4-40 or the use according to any one of claim 3-40, wherein binding domain B1 binds a DC target specifically expressed on mature DCs.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The bispecific polypeptide according to any one of claim 1 or 4-41 or the method according to any one of claim 2 or 4-41 or the use according to any one of claim 3-41, wherein binding domain B1 binds a DC target specifically expressed on immature DCs.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The bispecific polypeptide according to any one of claim 1 or 4-42 or the method according to any one of claim 2 or 4-42 or the use according to any one of claim 3-42, wherein the binding of domain B1 is capable of targeting cDC1.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The bispecific polypeptide according to any one of claim 1 or 4-43 or the method according to any one of claim 2 or 4-43 or the use according to any one of claim 3-43, wherein binding domain B1 binds a target selected from: XCR-1, CR-1, CLEC9A, DEC-205, CD1c, Dec-1, CD11b, CD11c, CD40.

### Claim 45 (depends on 42)

The bispecific polypeptide or method or use according to claim 42, wherein binding domain B1 binds a target selected from: DEC-205 and CD40.

### Claim 46 (depends on 45)

The bispecific polypeptide or method or use according to claim 45, wherein binding domain B1 binds CD40.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The bispecific polypeptide according to any one of claim 1 or 4-46 or the method according to any one of claim 2 or 4-46 or the use according to any one of claim 3-46, wherein binding domain B1 comprises one or more heavy chain CDR sequences selected from those in Table C(1) and/or wherein binding domain B1 comprises one or more light chain CDR sequences selected from those in Table C(2).

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The bispecific polypeptide according to any one of claim 1 or 4-47 or the method according to any one of claim 2 or 4-47 or the use according to any one of claim 3-47, wherein binding domain B1 comprises one, two or three light chain CDR sequences from a particular row for an individual antibody reference in Table C(2), and/or one, two or three heavy chain CDR sequences from the corresponding row for the antibody with the same reference in Table C(1).

### Claim 49 (depends on 47, 48)

The bispecific polypeptide or method or use according to claim 47 or 48, wherein binding domain B1 comprises all three heavy chain CDR sequences of a particular antibody reference as shown in Table C(1), and/or all three light chain CDR sequences of an antibody reference as shown in Table C(2), or wherein binding domain B1 comprises a heavy chain VH sequence and/or a light chain VL sequence as shown in Table A.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The bispecific polypeptide according to any one of claim 1 or 4-49 or the method according to any one of claim 2 or 4-49 or the use according to any one of claim 3-49, wherein binding domain B2 binds to a tumour cell-associated antigen selected from the group consisting of:
(a) products of mutated oncogenes and tumour suppressor genes;
(b) overexpressed or aberrantly expressed cellular proteins;
(c) tumour antigens produced by oncogenic viruses;
(d) oncofetal antigens;
(e) altered cell surface glycolipids and glycoproteins;
(f) cell type-specific differentiation antigens;
(g) hypoxia-induced antigens;
(h) tumour peptides presented by MHC class I;
(i) epithelial tumour antigens;
(j) haematological tumour-associated antigens;
(k) cancer testis antigens; and
(l) melanoma antigens.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The bispecific polypeptide according to any one of claim 1 or 4-50 or the method according to any one of claim 2 or 4-50 or the use according to any one of claim 3-50, wherein the tumour cell-associated antigen is selected from the group consisting of 5T4, CD20, CD19, MUC-1, carcinoembryonic antigen (CEA), CA-125, CO17-1A, EpCAM, HER2, HER3, EphA2, EphA3, DR4, DR5, FAP, OGD2, VEGFR, EGFR, NY-ESO-1, survivin, TROP2, WT-1.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The bispecific polypeptide according to any one of claim 1 or 4-51 or the method according to any one of claim 2 or 4-51 or the use according to any one of claim 3-51, wherein the tumour cell-associated antigen is an oncofetal antigen.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The bispecific polypeptide according to any one of claim 1 or 4-52 or the method according to any one of claim 2 or 4-52 or the use according to any one of claim 3-52, wherein the tumour cell-associated antigen is 5T4.

### Claim 54 (depends on 53)

The bispecific polypeptide or method or use according to claim 53, wherein the tumour cell-associated antigen is selected from the group consisting of CD20, EGFR, EpCAM and HER2.

### Claim 55 (depends on 54)

The bispecific polypeptide or method or use according to claim 54, wherein the tumour cell-associated antigen is EpCAM.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The bispecific polypeptide according to any one of claim 1 or 4-55 or the method according to any one of claim 2 or 4-55 or the use according to any one of claim 3-55, wherein binding domain B2 comprises one or more heavy chain CDR sequences selected from those in Table D(1) and/or wherein binding domain B2 comprises one or more light chain CDR sequences selected from those in Table D(2).

### Claim 57 (depends on 56)

The bispecific polypeptide or method or use according to claim 56, wherein binding domain B2 comprises one, two or three light chain CDR sequences from a particular row for an individual antibody reference in Table D(2), and/or one, two or three heavy chain CDR sequences from the corresponding row for the antibody with the same reference in Table D(1).

### Claim 58 (depends on 56, 57)

The bispecific polypeptide or method or use according to claim 56 or 57, wherein binding domain B2 comprises all three heavy chain CDR sequences of a particular antibody reference as shown in Table D(1), and/or all three light chain CDR sequences of an antibody reference as shown in Table D(2), or wherein binding domain B2 comprises a heavy chain VH sequence and/or a light chain VL sequence as shown in Table B.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The bispecific polypeptide according to any one of claim 1 or 4-58 or the method according to any one of claim 2 or 4-58 or the use according to any one of claim 3-58, wherein:
(a) B1 comprises the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1132 (SEQ ID NOs: 77, 78 and 79 and/or SEQ ID NOs: 97, 98 and 99) and B2 comprises the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody Solitomab (SEQ ID NOs: 115, 116, and 117 and/or SEQ ID NOs: 146, 147, and 148); or
(b) B1 comprises the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1132 (SEQ ID NOs: 77, 78 and 79 and/or SEQ ID NOs: 97, 98 and 99) and B2 comprises the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 2992 (SEQ ID NOs: SEQ ID NOs: 137, 138, and 139 and/or SEQ ID NOs: 163, 98, and 164); or
(c) B1 comprises the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1132 (SEQ ID NOs: 77, 78 and 79 and/or SEQ ID NOs: 97, 98 and 99) and B2 comprises the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody Trastuzumab (SEQ ID NOs: 131, 132 and 133 and/or SEQ ID NOs: 158, 159, and 160).

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The bispecific polypeptide according to any one of claim 1 or 4-59 or the method according to any one of claim 2 or 4-59 or the use according to any one of claim 3-59, wherein B1 comprises a heavy chain comprising the sequence of SEQ ID NO: 191, and a light chain comprising the sequence of SEQ ID NO: 192, and/or B2 comprises a heavy chain comprising the sequence of SEQ ID NO: 193, and a light chain comprising the sequence of SEQ ID NO: 194.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The bispecific polypeptide according to any one of claim 1 or 4-60 or the method according to any one of claim 2 or 4-60 or the use according to any one of claim 3-60, wherein binding domain B1 is an IgG and binding domain B2 is an scFv.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The bispecific polypeptide according to any one of claim 1 or 4-60 or the method according to any one of claim 2 or 4-60 or the use according to any one of claim 3-60, wherein binding domain B1 is an scFv and binding domain B2 is an IgG.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The bispecific polypeptide according to any one of claim 1 or 4-60 or the method according to any one of claim 2 or 4-60 or the use according to any one of claim 3-60, wherein binding domain B1 is an IgG and binding domain B2 is a Fab.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The bispecific polypeptide according to any one of claim 1 or 4-60 or the method according to any one of claim 2 or 4-60 or the use according to any one of claim 3-60, wherein binding domain B1 is a Fab and binding domain B2 is an IgG.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The bispecific polypeptide according to any one of claim 1 or 4-64 or the method according to any one of claim 2 or 4-64 or the use according to any one of claim 3-64, wherein the tumour cell expressing the tumour-cell associated antigen is a solid tumour cell.

### Claim 66 (depends on 65)

The bispecific polypeptide or method or use according to claim 65, wherein the solid tumour is selected from the groups consisting of renal cell carcinoma, colorectal cancer, lung cancer, prostate cancer, breast cancer, melanomas, bladder cancer, brain/CNS cancer, cervical cancer, oesophageal cancer, gastric cancer, head/neck cancer, kidney cancer, liver cancer, leukaemia, lymphomas, ovarian cancer, pancreatic cancer and sarcomas.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The bispecific polypeptide according to any one of claim 1 or 4-66 or the method according to any one of claim 2 or 4-66 or the use according to any one of claim 3-66, wherein binding domain B2 binds to the tumour cell-associated antigen with a KD of less than 100×10−9M, for example less than 10×10−9M or less than 5×10−9M.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

A bispecific polypeptide as defined in any one of claims 1-67.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

A method of predicting responsiveness of a patient to a cancer therapy comprising administration of the bispecific polypeptide of any of claims 1 to 68, wherein the method comprises:
(a) obtaining a sample comprising tumour cells and/or tumour-derived extracellular vesicles from the patient;
(b) measuring the amount or frequency of TAA-positive cells or TAA-positive EV in the obtained sample;
(c) classifying the patient as likely to respond to the therapy if the amount or frequency of TAA-positive cells or TAA-positive EV in the obtained sample is at least 0.25%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%; or classifying the patient as not likely to respond to the therapy if the amount or frequency of TAA-positive cells or TAA-positive EV in the obtained sample is less than 0.1%.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

A method of predicting responsiveness of a patient to a cancer therapy comprising administration of the bispecific polypeptide of any of claims 1 to 68, wherein the method comprises:
a) obtaining a sample from a patient;
b) measuring the concentration of TAA-positive EV in the obtained sample;
c) classifying the patient as likely to respond to the therapy if the concentration of TAA-positive EV in the sample is at least 1×106 EVs/ml or 1×107 EVs/ml or 1×108 EVs/ml or 1×109 EVs/ml or 1×1010 EVs/ml; or classifying the patient as not likely to respond to the therapy if the concentration of TAA-positive EV in the obtained sample is less than 1×105 EVs/ml.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

A method of predicting responsiveness of a patient to a cancer therapy comprising administration of the bispecific polypeptide of any of claims 1 to 68, wherein the method comprises:
a) obtaining a sample from a patient;
b) measuring the total protein concentration of TAA-positive EVs in the obtained sample;
c) classifying the patient as likely to respond to the therapy if the total protein concentration of TAA-positive EVs in the sample is at least 0.075 mg/ml, 0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.6 mg/ml, 0.7 mg/ml, 0.8 mg/ml, 0.9 mg/ml, 1 mg/ml or 1.5 mg/ml; or classifying the patient as not likely to respond to the therapy if the total protein concentration of TAA-positive EVs is less than 0.05 mg/ml, optionally wherein the EVs are exosomes.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

A method of predicting responsiveness of a patient to a cancer therapy comprising administration of the bispecific polypeptide of any of claims 1 to 68, wherein the method comprises:
a) obtaining a sample from a patient;
b) measuring the density of TAAs on one or more tumour cell in the obtained sample;
c) classifying the patient as likely to respond to the therapy if the density of the TAAs is above 30,000 per tumour cell.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any one of claims 69 to 72, further comprising the step (d) of treating a patient who has been classified as likely to respond to therapy in step (c) with the bispecific polypeptide of any one of claims 1 to 68.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

A method of identifying a patient suitable for treatment of cancer with the bispecific polypeptide of any of claims 1 to 68, wherein the method comprises:
(a) obtaining a sample comprising tumour cells and/or tumour-derived extracellular vesicles from the patient;
(b) measuring the amount or frequency of TAA-positive cells or TAA-positive EV in the obtained sample;
(c) identifying the patient as suitable for treatment if the amount or frequency of TAA-positive cells or TAA-positive EV in the obtained sample is at least 0.25%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

A method of identifying a patient suitable for treatment of cancer with the bispecific polypeptide of any of claims 1 to 68, wherein the method comprises:
(a) obtaining a sample from a patient;
(b) measuring the concentration of TAA-positive EV in the obtained sample;
(c) identifying the patient as suitable for treatment if the concentration of TAA-positive EV in the sample is at least 1×106 EVs/ml or 1×107 EVs/ml or 1×108 EVs/ml or 1×109 EVs/ml or 1×1010.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

A method of identifying a patient suitable for treatment of cancer with the bispecific polypeptide of any of claims 1 to 68, wherein the method comprises:
(a) obtaining a sample from a patient;
(b) measuring the total protein concentration of TAA-positive EVs in the obtained sample;
(c) identifying the patient as suitable for treatment if the total protein concentration of TAA-positive EVs in the sample is at least 0.075 mg/ml, 0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.6 mg/ml, 0.7 mg/ml, 0.8 mg/ml, 0.9 mg/ml, 1 mg/ml or 1.5 mg/ml, optionally wherein the EVs to be measured are exosomes.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

A method of f identifying a patient suitable for treatment of cancer with the bispecific polypeptide of any of claims 1 to 68, wherein the method comprises:
a) obtaining a sample from a patient;
b) measuring the density of TAAs on one or more tumour cell in the obtained sample;
c) identifying the patient as suitable for treatment if the density of the TAAs is above 30,000 per tumour cell.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 74, 75, 76, 77)

The method of any one of claims 74 to 77, further comprising the step (d) of treating a patient who has been classified as suitable for treatment in step (c) with the bispecific polypeptide of any one of claims 1 to 68.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

A bispecific polypeptide according to any one of claims 1 to 68 for use in targeting DCs and TAAs.

### Claim 80

An isolated nucleic acid molecule encoding a bispecific polypeptide according to any one of the preceding claims, or a component polypeptide chain thereof.

### Claim 81 (depends on 80)

The nucleic acid molecule according to claim 80 wherein the molecule is a cDNA molecule.

### Claim 82 (depends on 80, 81)

The nucleic acid molecule according to claim 80 or 81 encoding an antibody heavy chain or variable region thereof.

### Claim 83 (depends on 80, 81, 82)

The nucleic acid molecule according to any one of claims 80 to 82 encoding an antibody light chain or variable region thereof.

### Claim 84 (depends on 80, 81, 82, 83)

A vector comprising a nucleic acid molecule according to any one of claims 80 to 83.

### Claim 85 (depends on 84)

The vector according to claim 84 wherein the vector is an expression vector.

### Claim 86 (depends on 80, 81, 82, 83, 84, 85)

A recombinant host cell comprising a nucleic acid molecule according to any one of claim 80 to 83 or a vector according to claim 84 or 85.

### Claim 87 (depends on 86)

The host cell according to claim 86 wherein the host cell is a bacterial cell.

### Claim 88 (depends on 86)

The host cell according to claim 86 wherein the host cell is a mammalian cell.

### Claim 89 (depends on 86)

The host cell according to claim 86 wherein the host cell is a human cell.

### Claim 90 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 86, 87, 88, 89)

The method for producing bispecific polypeptide according to any one of claims 1 to 68, the method comprising culturing a host cell as defined in any of claims 86 to 89 under conditions which permit expression of the bispecific polypeptide or component polypeptide chain thereof.

### Claim 91

A method of producing a DC-TAA bispecific polypeptide, the method comprising:
(a) measuring a tumour cell or tumour cell-derived extracellular vesicle to determine density of a tumour-cell associated antigen
(b) if the density is above 30,000 on tumour cell (for example, 100,000 on tumour cell), then classifying the TAA as a suitable target for a DC-TAA bsAb
(c) producing a bispecific polypeptide capable of targeting the TAA, and also capable of targeting a DC.

### Claim 92 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The pharmaceutical composition comprising an effective amount of bispecific polypeptide according to any one of the claims 1 to 68 and a pharmaceutically-acceptable diluent, carrier or excipient.

### Claim 93 (depends on 92)

The pharmaceutical composition according to claim 92 adapted for parenteral delivery.

### Claim 94 (depends on 92)

The pharmaceutical composition according to claim 92 adapted for intravenous delivery.

### Claim 95 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The bispecific polypeptide according to any one of claim 1 or 4-68 or the method according to any one of claim 2 or 4-68 or the use according to any one of claim 3-68, wherein the bispecific polypeptide binds a TAA which is present on TAA-positive EVs, and the concentration of TAA-positive EVs is at least 1×106 EVs/ml or 1×107 EVs/ml or 1×108 EVs/ml or 1×109 EVs/ml or 1×1010 EVs/ml.

### Claim 96 (depends on 95)

The bispecific polypeptide or method or use according to claim 95, wherein the polypeptide or composition is for use in treating a patient with a neoplastic disorder comprising tumour cells, wherein the bispecific polypeptide binds a TAA which is present on TAA-positive EVs, and the total protein concentration of the TAA-positive EVs is at least 0.075 mg/ml, 0.1 mg/ml, 0.2 mg/ml, 0.3 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.6 mg/ml, 0.7 mg/ml, 0.8 mg/ml, 0.9 mg/ml, 1 mg/ml or 1.5 mg/ml, optionally wherein the EVs are exosomes.

### Claim 97 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 95, 96)

The bispecific polypeptide according to any one of claim 1, 4-68, 95 or 96 or the method according to any one of claim 2, 4-68, 95 or 96 or the use according to any one of claim 3-68, 95 or 96. wherein the neoplastic disorder is associated with the formation of solid tumours within the subject's body.

### Claim 98 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 95, 96, 97)

The bispecific polypeptide according to any one of claim 1, 4-68 or 95-97 or the method according to any one of claim 2, 4-68 or 95-97 or the use according to any one of claim 3-68 or 95-97, wherein the tumour cells are cells of a low T cell infiltration tumour.

### Claim 99 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 85, 86, 87, 88, 89, 95, 96, 97, 98)

The bispecific polypeptide according to any one of claim 1, 4-68 or 95-98 or the method according to any one of claim 2, 4-68 or 95-98 or the use according to any one of claim 3-68 or 85-89, wherein the tumour cells express one or more tumour-cell associated antigens selected from the group consisting of CD20, 5T4, EGFR, EpCAM and HER2.

### Claim 100 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 95, 96, 97, 98, 99)

The bispecific polypeptide according to any one of claim 1, 4-68 or 95-99 or the method according to any one of claim 2, 4-68 or 95-99 or the use according to any one of claim 3-68 or 95-99, wherein the solid tumour is selected from the group consisting of prostate cancer, breast cancer, lung cancer, colorectal cancer, melanomas, bladder cancer, brain/CNS cancer, cervical cancer, oesophageal cancer, gastric cancer, head/neck cancer, kidney cancer, liver cancer, leukaemia, lymphomas, ovarian cancer, pancreatic cancer and sarcomas.

### Claim 101 (depends on 100)

The bispecific polypeptide or method or use according to claim 100, wherein the solid tumour is selected from the groups consisting of renal cell carcinoma, colorectal cancer, lung cancer, prostate cancer, ovarian cancer and breast cancer.

### Claim 102 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 95, 96, 97, 98, 99, 100, 101, 1019)

The bispecific polypeptide according to any one of claim 1, 4-68 or 95-101 or the method according to any one of claim 2, 4-68 or 95-101 or the use according to any one of claim 3-68 or 95-1019, wherein the polypeptide is for use in combination with one or more additional therapeutic agents.

### Claim 103 (depends on 103)

The bispecific polypeptide or method or use according to claim 103, wherein the one or more additional therapeutic agents is/are an immunotherapeutic agent that binds a target selected from the group consisting of PD-1/PD-L1, CTLA-4, CD137, OX40, GITR, LAG3, TIM3, CD27, VISTA and KIR.

### Claim 104 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 92, 93, 94)

A kit comprising:
(a) the bispecific polypeptide of any one of claims 1 to 69, or the pharmaceutical composition of any one of claims 92 to 94; and
(b) one or more additional therapeutic agents, optionally wherein the one or more additional therapeutic agents is/are an immunotherapeutic agent that binds a target selected from the group consisting of PD-1/PD-L1, CTLA-4, CD137, OX40, GITR, LAG3, TIM3, CD27 and KIR.

### Claim 105

A bispecific polypeptide substantially as described herein with reference to the description and figures.

### Claim 106

A polynucleotide substantially as described herein with reference to the description and figures.

### Claim 107

A pharmaceutical composition substantially as described herein with reference to the description and figures.

### Claim 108

Use of a bispecific polypeptide substantially as described herein with reference to the description and figures.

### Claim 109

A method of treatment substantially as described herein with reference to the description and figures.
